Copyright © Inderes 2011 - present. All rights reserved.
Pörssitiedote

Update on NeoDynamics’ Management Team

NeoDynamics
Lataa tiedote

Anna Eriksrud announces desire to retire as CEO of NeoDynamics.

Anna Eriksrud, CEO joined NeoDynamics in 2016 and led the company from the start-up phase through to FDA clearance of NeoNavia ® and commercial launch in Europe and the US.

 “Well into my sixties, it is time for me to consider my next chapter and prepare for an orderly management transition at NeoDynamics. When I joined NeoDynamics in 2016, I was hired to bring the company forward to commercial proof of concept, including establishing a network of KOL ambassadors at leading hospitals, and we’re now very close to attaining these important milestones. I am proud of the results we have achieved, and not least the 2022 FDA clearance in the US.” says Anna Eriksrud, CEO, NeoDynamics.

Ingrid Salén, Chairman comments: “We are grateful to Anna for having safely navigated NeoDynamics through turbulent times. The Covid 19 pandemic, changing ownership structures and finetuning products have made the already challenging certification process and finding key stake holders even more difficult. Anna has taken on these many challenges with much energy and a clear vision. NeoDynamics is now well positioned to leverage our technology and achieve commercial success. Anna will remain until a new CEO is in place to ensure a smooth transition and will have an advisory role through 2024.”

For further information, please contact:
Ingrid Salén, Chairman NeoDynamics AB, phone +46 657 1515 or e-mail Ingrid.salen@rentability.se
Anna Eriksrud, CEO NeoDynamics AB, phone +46708 444 966 or e-mail anna.eriksrud@neodynamics.com

About NeoDynamics
NeoDynamics AB is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in Europe and launches in USA during 2023. NeoDynamic’s shares are listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company’s Certified Adviser is Redeye AB.

About NeoNavia
NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumor whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.

About Karolinska Institute
The Karolinska Institute is consistently ranked amongst the world's best medical schools, ranking 6th worldwide for medicine in 2021. The Nobel Assembly at the Karolinska Institute awards the Nobel Prize in Physiology or Medicine.

Attachments
Update on NeoDynamics’ Management Team

Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.